News
BMS’ sponsored programme selects four research projects to investigate viral diseases
Bristol-Myers Squibb's (BMS) European medical education programme Partnering for Cure has selected four research projects, designed to investigate new ways to cure viral diseases....
Clinical Trials
Sanofi and Regeneron report positive Phase IIb trial results of dupilumab in asthma patients
Sanofi and Regeneron Pharmaceuticals have reported positive results from the interim analysis of a dose-ranging Phase IIb trial of dupilumab, a fully-human monoclonal antibody,...
Clinical Trials
Sarepta doses first patient in eteplirsen trial to treat duchenne muscular dystrophy
US-based Sarepta Therapeutics has started dosing patients in a clinical trial of its lead exon-skipping therapeutic candidate eteplirsen to treat Duchenne muscular dystrophy (DMD)....
News
Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence
Cambridge, MA, USA and Krakow, Poland, November 7, 2014 / B3C newswire / -Felicitex Therapeutics, a leader in the diagnostics and development of therapeutics...
Press Releases
New Oncology to Collaborate with National Cancer Centre Singapore on Genetic Testing
Cologne, Germany, November 12, 2014 / B3C newswire / -New Oncology announced today that it has entered into a collaboration with the National Cancer...
News
LINDIS Biotech Consolidates Onco-Immune, Trifunctional, Bispecific Antibody IP and Know-How from TRION Pharma Establishing a New Basis for Capitalization and Growth
Munich, Germany, November 7, 2014 / B3C newswire / - Horst Lindhofer, CEO of LINDIS Biotech and inventor of the trifunctional antibody technology succeeded...
Press Releases
New Management Organisation of the Haselmeier Group
Zurich, Switzerland, November 10, 2014 / B3C newswire / - Haselmeier was able to successfully grow over the past few years, allowing the company...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read